{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:11:16Z","timestamp":1791803476137,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04031-z","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:03:54Z","timestamp":1743980634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4282-8609","authenticated-orcid":false,"given":"Marine","family":"Massy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-6965","authenticated-orcid":false,"given":"Stefanie","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helly","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0115-7021","authenticated-orcid":false,"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"4031_CR1","first-page":"1","volume":"02114","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;02114:1\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4031_CR2","unstructured":"U.S. Food & Drug Administration (FDA). FDA Adverse Event Reporting System. 2012. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 8 July 2024."},{"key":"4031_CR3","unstructured":"HCl Solutions. TOPIRAMATE Sandoz cpr pell 25 mg: info prof. 2024. https:\/\/compendium.ch\/product\/1128512-topiramat-sandoz-filmtabl-25-mg\/mpro. Accessed 16 July 2024."},{"key":"4031_CR4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"4031_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, J\u00f3dar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019;45:409\u201318.","journal-title":"Diabetes Metab"},{"key":"4031_CR6","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724\u201332.","journal-title":"Diabetes Care"},{"key":"4031_CR7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"4031_CR8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"4031_CR9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Sim\u00f3 R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obes Metab. 2018;20:889\u201397.","journal-title":"Diabetes, Obes Metab"},{"key":"4031_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40261-021-01110-w","volume":"42","author":"F Wang","year":"2022","unstructured":"Wang F, Mao Y, Wang H, Liu Y, Huang P. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2022;42:17\u201328.","journal-title":"Clin Drug Investig"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04031-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:04:10Z","timestamp":1743980650000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04031-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4031"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04031-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Massy M reports no competing interests. Marti S reports no competing interests. Hammer H received research support and travel grants within the last 5 years from Biogen, Merck, Roche & Bristol Myers Squibb, Teva, Johnson&Johnson, Novartis. All not related to that work. Hoepner R received speaker\/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Teva\/Mepha and Almirall. He received research support within the last 5 years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol-Myers Squibb. He also received research grants from the Swiss MS Society, the SITEM Insel Support Fund and is a member of the Advisory Board of the Swiss and International MS Society. He also serves as deputy editor in chief for Journal of Central Nervous System disease and is part of the ECTRIMS Young Investigator Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}